This company listing is no longer active
Aceragen Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Aceragen does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
n/a
Ausschüttungsquote
| Durchschnittlicher Branchenertrag | 1.9% |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | n/a |
| Gewinn pro Aktie | -US$4.88 |
| Prognose der Dividendenrendite | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if ACGN's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if ACGN's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
| Aceragen Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (ACGN) | n/a |
| Untere 25 % des Marktes (US) | 1.4% |
| Markt Top 25 % (US) | 4.3% |
| Branchendurchschnitt (Biotechs) | 1.9% |
| Analystenprognose (ACGN) (bis zu 3 Jahre) | n/a |
Bemerkenswerte Dividende: Unable to evaluate ACGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate ACGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as ACGN has not reported any payouts.